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Abstract: Besides being essential for correct development of the vertebrate nervous system the neurotrophins also play a 
vital role in adult neuron survival, maintenance and regeneration. In addition they are implicated in the pathogenesis of 
certain neurodegenerative diseases, and may even provide a therapeutic solution for some. In particular there have been a 
number of studies on the involvement of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) in the 
development of Alzheimer’s disease. This disease is of growing concern as longevity increases worldwide, with little 
treatment available at the moment to alleviate the condition. Memory loss is one of the earliest symptoms associated with 
Alzheimer’s disease. The brain regions first affected by pathology include the hippocampus, and also the entorhinal cortex 
and basal cholinergic nuclei which project to the hippocampus; importantly, all these areas are required for memory  
formation. Both NGF and BDNF are affected early in the disease and this is thought to initiate a cascade of events which 
exacerbates pathology and leads to the symptoms of dementia. This review briefly describes the pathology, symptoms and 
molecular processes associated with Alzheimer’s disease; it discusses the involvement of the neurotrophins, particularly 
NGF and BDNF, and their receptors, with changes in BDNF considered particularly in the light of its importance in  
synaptic plasticity. In addition, the possibilities of neurotrophin-based therapeutics are evaluated. 
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ALZHEIMER’S DISEASE: AN OVERVIEW 
  Alzheimer’s disease accounts for about 60% of all de-
mentias, and over 26 million people worldwide are reported 
to have Alzheimer’s disease [1], and it is likely that nearly 
double that number will suffer with some form of dementia. 
Dementia involves a progressive decline in mental function, 
usually including deficits in memory, language and cognitive 
processes. It is therefore not just the patients themselves who 
are affected by the disease but also the millions of carers, 
often unpaid, who are needed to look after them. Since the 
greatest risk factor of Alzheimer’s disease is age, the rapidly 
rising median age of the world’s population may result in a 
dramatic increase in the prevalence of the disease during the 
next decade [1]. The impact this will have on global 
healthcare systems is likely to be devastating. Understanding 
the underlying processes in the disease and providing new 
therapies will be paramount.  
  In 1907 Alois Alzheimer, a German psychiatrist and neu-
ropathologist, first described the symptoms of short-term 
memory loss and confusion, and linked it to the neuropathol-
ogy seen at post-mortem in a 51 year old patient Auguste 
Deter [2]. The typical pathology of this disease involves 
gross atrophy of the brain, with thinning of the grey matter in 
the cerebral cortex, enlarged ventricles indicating neuronal 
loss, microscopic extracellular amyloid plaques (comprising 
aggregated amyloid protein), intracellular neurofibrillary 
tangles (comprised of aggregated tau protein), and cere-
brovascular amyloid (amyloid protein surrounding the blood 
vessels) (see Fig. 1).  
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  In Alzheimer’s disease, many areas in the brain have 
amyloid plaques and neurofibrillary tangles present,   
especially the frontal, temporal and parietal cortices, the   
hippocampus, and the cholinergic nuclei of the basal   
forebrain (ChBF) [3-4]. Amyloid plaques do not seem to 
have a definite pattern of deposition, perhaps due to the 
many mechanisms able to clear these extracellular proteins, 
whereas the deposition of intracellular neurofibrillary tangles 
seems to follow a well defined pattern [5]. They form first  
in the transentorhinal cortex, then spread sequentially to   
the entorhinal cortex, to areas of the hippocampus and   
then outwards to the cerebral cortex. Numerous studies have 
indicated that one of the earliest changes in Alzheimer’s   
disease involves the loss of synapses, which correlates with 
mental decline [6], eventually leading to marked cell loss 
throughout a number of brain areas. The symptoms of the 
disease therefore follow the slow progression of destruction 
throughout the brain, beginning with the inability to   
make new memories, a process which is dependent on the 
hippocampus and its input from the ChBF.  
THE NEUROTROPHINS: A BRIEF INTRODUCTION 
TO THEIR IMPORTANCE IN THE HIPPOCAMPUS 
AND THE CHBF  
  The neurotrophins are a family of four similar proteins: 
NGF, BDNF, NT-3 and NT-4. They all bind with nanomolar 
affinity to a pan-neurotrophin receptor p75NTR, and each 
bind separately, with picomolar affinity, to specific tyrosine 
kinase receptors (Trks): NGF binds TrkA, BDNF and NT-4 
bind TrkB, and NT-3 binds TrkC. Further details of their 
mode of action in development and disease can be found 
elsewhere in this issue and in reviews [7]. 
  Studies on the importance of the neurotrophins in   
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BDNF and their effect on neurons of the hippocampus and 
the ChBF. The cholinergic basal forebrain neurons express 
TrkA receptors which respond to NGF by promoting and 
maintaining synaptic contact with the neurons of the hippo-
campus and cortex. In the hippocampus BDNF is a vital 
component of synaptic plasticity and memory formation. 
LTP (long term potentiation) is a prerequisite for memory 
formation and is maintained by the action of BDNF at TrkB, 
which results in structural changes at the synapse. TrkB re-
ceptors are also present on some cholinergic neurons and 
help to support cholinergic function. Thus interruption of 
expression of either NGF or BDNF, or a change in the levels 
of TrkA or TrkB receptors, may result in impaired memory 
formation and neuronal degeneration. Indeed, the expression 
of both of these trophic factors and their receptors is affected 
early in the disease process and therefore appropriate   
neurotrophin-related therapeutic solutions require an under-
standing of how this happens and how the situation may be 
remedied. 
THE CHOLINERGIC HYPOTHESIS 
  In the late 1970s and early 1980s there were reports   
of considerable deficits in the function of the cholinergic 
system in post-mortem tissue, including reductions in the 
activity of choline acetyltransferase, the enzyme responsible 
for the synthesis of acetylcholine [8-10]. Furthermore,   
decreased choline uptake and acetylcholine release was   
reported in biopsy samples from early Alzheimer’s patients 
[8]. In addition cortical acetylcholinesterase activity has   
been shown to be reduced [11,12]. The changes in choline 
acetyltransferase activity and acetylcholinesterase however, 
are not seen in mild cognitive impairment (MCI) and it may 
be that they are a result of other changes in cholinergic cells, 
such as loss of TrkA and reduction of NGF, which have been 
reported in MCI [13,14].  
  The cholinergic basal nuclei comprising the septal   
nucleus, diagonal band of Broca and the nucleus basalis of 
Meynert (nbM), collectively called the cholinergic basal 
forebrain nuclei (ChBF), provides the major cholinergic   
innervation to the hippocampus and cerebral cortices [15,16], 
and thus are important in memory function and attention 
[17,18].  
  There is a wealth of evidence to show that this cholinergic 
system is involved in cognitive processes in rats, monkeys, 
and humans. Lesions of the cholinergic septum and diagonal 
band of Broca in rats result in a number of memory deficits 
such as impairment in maze performance [19, 20], and   
similar lesions affect memory and cognition in primates   
[21, 22]. Administration of cholinergic antagonists, such   
as scopolamine, also result in the inability to acquire new 
information in primates [21] and cause learning impairments 
in human volunteers [23].  
  The ‘Cholinergic Hypothesis’ of Alzheimer’s disease 
suggests that this loss of cholinergic function in the ChBF 
and the cerebral cortex contributes to the deterioration in 
cognitive function seen in patients with Alzheimer’s disease 
[24]. Rivastigmine, donepezil and galantamine are routinely 
administered cholinesterase inhibitors (often abbreviated to 
CEI) used to counteract this cholinergic deficit. They inhibit 
the activity of acetylcholinesterase which degrades   
acetylcholine in the synapse, and are successful at reducing 
symptoms in approximately half of patients prescribed them. 
Although improvements in cognition are usually no greater 
than five points on the ADAS-cog scale, more obvious   
improvements are noted by carers in behavioural and   
functional aspects such as attention and social engagement, 
which can be maintained for four to five years [25].   
Unfortunately, their use is ultimately ephemeral and   
gradually becomes insufficient to maintain the cholinergic 
signal; presumably as fewer and fewer synapses remain 
which are able to release acetylcholine. However, recent 
evidence suggests that memantine, a glutamatergic N-methyl 
D-aspartate receptor (NMDAR) antagonist may also   
protect cholinergic function. Memantine, which has been 
recommended for use in moderate Alzheimer's disease,   
protects against amyloid-induced loss of basal forebrain   
cholinergic fibres and the resultant behavioural deficits [26]. 
This may be via a number of neuroprotective mechanisms, 
and it is possible that a combination of memantine and   
cholinesterase inhibitors may prove of benefit. 
THE AMYLOID HYPOTHESIS 
APP Processing 
  Despite the fact that the cholinesterase inhibitors are the 
current mainstay of Alzheimer drug treatment, the majority 
of new drug targets are not aimed at cholinergic neurons. 
They are aimed mainly at preventing formation of amyloid 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Gross atrophy of the human brain in Alzheimer’s   
disease [b] compared with normal [a]. In moderate to severe   
Alzheimer’s disease, enlargement of the lateral ventricles is evident, 
due to cell loss, and thinning of the gyri, producing widened sulci. 
The hippocampus appears shrunken. Histochemical staining with 
certain dyes such as Thioflavin S make visible neurons containing 
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or clearing it, or to a lesser extent, preventing or clearing 
neurofibrillary tangles. Amyloid or A is a 4kDa peptide 
derived from the larger amyloid precursor protein (APP) by 
the sequential cutting of two enzymes, beta- and gamma-
secretase. Beta-secretase, cloned independently by four sepa-
rate groups in 1999, is now known as BACE 1 (-APP site 
cleaving enzyme 1) [27]. It cleaves the N-terminal portion of 
APP to leave a 99 amino acid C-terminal portion (C99) 
which includes the single transmembrane and cytosolic   
region of APP. Gamma-secretase is now known to be a   
complex comprised of four proteins including Presenilin 1 
(or 2), which has been shown to be the catalytic subunit of 
the enzyme quartet [28, 29]. It is this enzyme that cleaves 
APP within the transmembrane region to produce the A 
peptide (see Fig. 2). The majority of A produced is 40 
amino acids in length (A40), however the site of cleavage 
may vary and a small proportion of A42 may form, which 
has a greater propensity to fibrillise. Because of this, the 42 
amino acid species usually aggregates into parenchymal 
plaques, whereas the 40 amino acid form, which is more 
soluble, is cleared to the blood vessels before it deposits around 
the vessel cell walls causing cerebrovascular amyloid.  
 
 
 
 
 
 
 
 
 
Fig. (2). Production of A by cleavage of APP (amyloid precursor 
protein).  Beta-secretase and gamma secretase sequentially   
cleave APP to form A, which then aggregates to form amyloid 
plaques. 
Familial Alzheimer’s Disease 
  The ‘Amyloid Hypothesis’ [30, 31]) proposes that   
increased A formation, deposition or decreased clearance is 
sufficient to produce all the neuropathology and associated 
symptoms leading to dementia in Alzheimer’s disease. This 
hypothesis followed the discovery that mutations in the APP 
gene (present on chromosome 21), can lead to an increase  
in the formation of the A peptide. These mutations are   
autosomal dominant and therefore families carrying the   
gene can be traced and studied. Such familial cases usually 
present symptoms before 65 years and thus are considered  
to be presenile or early onset. Individuals with Down’s   
syndrome or Trisomy 21 have a replication of all or part   
of chromosome 21 (containing the APP gene), and thus   
an increase in APP gene dosage. It is thought that this is   
responsible for the finding that Down’s sufferers usually 
present symptoms of Alzheimer’s disease in their forties.  
  Familial Alzheimer’s disease is associated with   
mutations in one of three possible genes: APP on   
chromosome 21, PSEN1 on chromosome 14 or PSEN2   
on chromosome 1. Mutations in PSEN1, which is the gene 
coding for the presenilin 1 protein, have been shown to result 
in an increase in the ratio of A42:A40, by shifting the 
cleavage site within the transmembrane region of APP. A 
has been reported as ‘toxic’ to the cell in numerous studies; 
the reasons given are manifold [32, 33]. A42 is reported to 
be more noxious than the A40 form, thus an increase in 
production of the longer peptide is thought likely to accelerate 
the processes underlying Alzheimer’s disease. This may   
be exemplified by the finding that some mutations in the 
PSEN1 gene lead to an onset of symptoms of Alzheimer’s 
disease patients in their twenties or thirties.  
A Toxicity and Sporadic Alzheimer’s Disease 
  The production of A occurs in normal, as well as   
Alzheimer brain [34]. However, the majority of APP   
processing in both normal and Alzheimer brain occurs with 
cleavage by the enzyme alpha-secretase, rather than   
beta-secretase. Alpha secretase activity is produced by the 
action of one or more of the ADAMs (A disintegrin and   
metalloproteinase) family members, most notably ADAM 17 or 
TACE (TNFalpha converting enzyme) [35]. Thus sequential 
cleavage of APP by alpha-secretase (instead of beta-secretase) 
and subsequently gamma-secretase does not result in the 
formation of A, but a smaller non toxic peptide called p3.  
  The symptoms of sporadic (non familial) cases, which 
are usually late onset and comprise over 95% of cases, may 
not necessarily result from an increased production of A. 
These cases may have reduced clearance or some other   
difference which results in increased sensitivity to the effects 
of A. Nevertheless, substantial increases in BACE1 activity 
have been seen in late-onset Alzheimer brain tissue [36], 
suggesting that there is an increased production of A, at 
least in some patients.  
  Numerous studies have shown that A is toxic to neurons 
by means of a number of different mechanisms. The brain 
has a high rate of oxygen consumption and low levels   
of protective, anti-oxidant enzymes, and thus tends to be 
vulnerable to free radical damage. A is known to induce 
production of reactive  oxygen species (ROS), which   
are damaging to cells, and much of the initial damage may 
occur in the mitochondria. A has been shown to cause an 
increase in intracellular H2O2 that disturbs the membrane 
environment of metabolic pathway enzymes and causes 
leakage through mitochondrial membranes, and it is the   
diffusible, oligomeric form of A which is generally thought 
to be most damaging. In addition, A has been shown to 
bind to and disrupt a number of receptors [37], including 
alpha 7 nicotinic acetylcholine receptor, RAGE (receptor for 
advanced glycosylation end-products), NMDA-R (N-methyl-
D-aspartate receptor), low-density lipoprotein receptor-
related protein (LRP) and p75NTR [38]. This binding   
produces a variety of downstream effects, some of which 
may have deleterious consequences [37]. 
Neurofibrillary Tangle Formation 
  To satisfy the Amyloid Hypothesis, the production of   
A must also result in an increase in neurofibrillary tangle 
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abnormal intracellular aggregation of peptides produced from 
the cleavage of the protein tau. Tau is a microtubule associated 
protein which interacts with tubulin and promotes its assembly 
into microtubules, and also stabilizes them within axons. 
Phosphorylation of the tau protein may cause it to separate 
from the microtubules and aggregate into paired helical   
filaments in the cytoplasm [39]. Analysis of the core protein of 
these aggregates reveals a 12kDa protein consisting largely 
of the microtubule binding domains from the middle of the 
tau protein, cleaved at the N- and C-terminal ends from the full 
length tau molecule; these eventually form neurofibrillary 
tangles. The evidence for the ability of A to directly   
influence the creation of neurofibrillary tangles is sparse; 
however one of the most convincing studies describes the 
injection of A42 into the brains of transgenic mice which 
have a mutation in tau (P301L: which causes neurofibrillary 
tangle formation in the mice). Less than three weeks after 
injection there was a fivefold increase in tangle formation,  
in the area of the amygdala from where neurons project   
to the injection sites [40]. A proposed mechanism would   
be an increase in phosphorylation of tau due to the presence 
of A, resulting in the inability of tau to remain bound to 
microtubules leading to aggregation within the neuron. 
  Despite the finding that A production can act as a   
trigger for neurofibrillary tangle formation and subsequently 
dementia, there are many researchers who consider the 
changes in tau as a more important determining factor for 
dementia. In agreement with this, the extent of neurofibrillary 
tangle formation in Alzheimer’s disease correlates more 
strongly with degree of dementia than does amyloid plaque 
formation [41]. In addition, FTDP-17 (frontotemporal   
dementia with Parkinsonism linked to chromosome 17; the 
gene coding for tau is on chromosome 17) does not present 
with amyloid deposition as a neuropathological feature,   
yet still produces a profoundly dementing condition with 
symptoms often appearing before the fifth decade. These 
include behavioural and personality changes, severe motor 
difficulties akin to Parkinsonism, and cognitive problems 
which interestingly, may not affect memory function.  
NGF AND ITS RECEPTORS IN THE CHBF 
Neurotrophic Factor Hypothesis 
  In 1981 a unifying hypothesis was proposed for the cause 
of amyotrophic lateral sclerosis, Parkinsonism, and   
Alzheimer’s disease [42]. This hypothesized that each of 
these disorders was due to the lack of a specific neurotrophic 
hormone. In the case of Alzheimer’s disease a trophic factor 
required for cholinergic survival would be insufficiently   
produced by target regions such as the hippocampus, with 
resulting neuronal loss. In reality, with a disease like   
Alzheimer’s which progresses over a number of decades,   
if the loss of such a neurotrophic factor were responsible   
for neuronal decline then it is likely that this loss would itself 
be resultant from some other insult or factor which had   
accumulated gradually. Nonetheless, as with consideration of 
the relative contributions of amyloid and tau to the disease 
process, it may be that loss of activity of such a neurotrophic 
factor may exacerbate effects of A such that the pathology 
precipitates dementia more readily. Two neurotrophic factor 
candidates for such a pivotal role in the progression of   
Alzheimer’s disease are NGF and BDNF.  
ChBF, NGF and its Receptors  
  Subsequent to the hypothesis proposed by Appel, normal 
brain levels of NGF mRNA were shown to correlate with  
the degree of ChBF innervation, with the highest NGF and 
NGF mRNA levels being present in the cerebral cortex and 
hippocampus [43]. By injection of radiolabelled NGF into 
the hippocampus or cerebral cortex, NGF was shown to be 
retrogradely transported from the terminals of ChBF neurons 
to their cell bodies [44]. NGF interacts with both the pan-
neurotrophin receptor  p75NTR [45] and the high-affinity 
NGF-specific receptor TrkA on the surface of the cholinergic 
neurons [46-47]. p75NGF (later named p75NTR) was the 
only named receptor for NGF until TrkA was identified in 
1991 [48]. p75NTR was shown by immunohistochemistry, 
in situ hybridisation and radiolabelled binding techniques to 
be almost exclusively located on neurons of the ChBF in rat, 
monkey and human brain, with some in the striatum and low 
levels in the cortex and hippocampus [49-54]. Over 80% of 
cholinergic neurons were shown to be p75NTR positive.  
  Later TrkA mRNA and protein was shown to be present 
in neurons of the ChBF [55-56]; with over 90% TrkA   
colocalisation with p75NTR, but with only TrkA not p75NTR 
expressed in the striatal neurons [56]. In addition ChBF   
neurons express TrkB or TrkC or a combination of these. It is 
NGF binding to the TrkA receptor that stimulates signalling 
pathways, mediating survival and growth effects [46]. 
ChBF Neurons in Alzheimer’s Disease 
  Thus ChBF neurons provide the major source of   
cholinergic innervation to the hippocampus and cerebral 
cortex, and these neurons are affected early in Alzheimer’s 
disease. Cholinergic projections show reduced function and 
ChBF neuronal cell bodies produce neurofibrillary tangles. 
In the 1980s a major loss of neurons from the ChBF   
was reported in Alzheimer brain [57]. Further studies using 
antibodies to p75NTR, showed relative sparing of the   
anterior nbM and septal nucleus with most loss being in the 
posterior part of the ChBF. In older patients (88 years mean 
age of death) little reduction in NGF receptor positive   
neurons was noted, although cell shrinkage was evident   
[58, 59], whereas studies of younger patients reported 
marked cell loss [60, 61]. This may indicate that patients 
suffering from a very late onset of the disease may have   
less cell loss in the ChBF, despite substantial loss of choline 
acetyltransferase activity in the cortex.  
NGF AND ITS RECEPTORS IN ALZHEIMER’S   
DISEASE 
NGF Levels in Alzheimer’s Disease 
  In the 1980s, in line with the neurotrophic factor   
hypothesis, the idea emerged that a loss of NGF in Alzheimer’s 
brain may account for the loss of cholinergic function. How-
ever, no change was found in NGF mRNA levels in Alzheimer’s 
disease cerebral cortex and hippocampus compared with 
normal brain [62]. Furthermore, measurements of NGF   
protein in Alzheimer’s disease brain unexpectedly showed 
either significant or non-significant increases in the cerebral 
cortex and hippocampus [63-64], although NGF levels in the 
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in ChBF NGF levels might be a failure in retrograde   
transport NGF from target tissues to the cell bodies. In a 
mouse model of Down’s syndrome (Trisomy 16), retrograde 
transport of radiolabelled NGF from the hippocampus to the 
septum was markedly reduced [66]. As mentioned above, 
Down’s syndrome sufferers, because of the extra gene copy 
of APP, invariably present with Alzheimer-type symptoms 
and pathology. Further studies in this mouse model related 
this to increased APP protein in the ChBF neurons [67]. 
NGF Receptors in Alzheimer’s Disease 
  The p75NTR receptor has a number of co-receptors, and 
can act in a ligand dependent or independent manner. In the 
presence of TrkA it can interact and facilitate an increase in 
affinity of NGF for TrkA [46, 68]. However, in combination 
with other receptors, p75NTR is able to induce apoptosis. 
Thus neuron cultures from p75NTR knockout mice showed 
reduced sensitivity to A-induced cell death. When crossed 
with transgenic mice with APP mutations (models of   
Alzheimer’s disease with amyloid plaque formation and 
memory deficits), p75NTR knockout mice showed a reduced 
degeneration in cholinergic neurites despite no reduction in 
A levels. This suggests that the major pathway by which 
A-induced cholinergic dysfunction occurs is mediated via 
p75NTR. Furthermore, p75NTR has been shown to bind A, 
resulting in JNK-mediated apoptosis [38]. 
  An early significant loss has been reported in the number 
of TrkA-positive neurons in basal forebrain in MCI (46%) 
and Alzheimer’s disease (56%) compared to normal [69], 
and this reduction is associated with cognitive decline [70, 
71]. In addition, using single cell expression profiling   
methods individual ChBF neurons showed downregulation 
of TrkA, TrkB, and TrkC expression during the progression 
of Alzheimer’s disease from MCI, whereas p75NTR mRNA 
levels remained stable even in the end stage of the disease. 
This is in agreement with earlier studies of basal forebrain 
membranes from Alzheimer’s disease brain in which no   
difference from normal was seen in p75NTR mRNA levels 
[72] or in NGF binding at p75NTR receptors [73]. 
NGF processing in Alzheimer’s Disease 
  NGF is produced as a 36kDa precursor protein (proNGF) 
which is cleaved to the mature form, by furin intracellularly 
or plasmin extracellularly. As previously mentioned, levels 
of NGF were unexpectedly found to be increased. However, 
it had been assumed that the NGF measured in the brain 
would be in its mature form; unfortunately the antibodies 
used were able to bind both the mature and the pro-forms, 
and it was only established much later that in human brain 
the predominant form is pro-NGF. ProNGF levels have now 
been shown to progressively increase during the disease 
process from MCI to end stage, and are associated with 
poorer performance on cognitive tests [74, 75]. 
  Evidence suggests that cortical cholinergic nerve terminals 
are dependent on endogenous NGF, and NGF has a role in 
the continual remodelling of cholinergic associated circuits 
in adulthood [76]. This leads to the question as to how an 
increase in proNGF may arise in Alzheimer’s disease, and 
the consequent effects of this. Investigation of the maturation 
and degradation of this protein provides some clues.  
  Furin and metalloproteases 3 and 7 process proNGF in 
the transGolgi network (TGN), and it has been generally 
assumed that proNGF is largely converted to NGF intra- 
cellularly. However Cuello and colleagues, have provided 
evidence that the conversion of proNGF to mature NGF   
is diminished in Alzheimer’s disease, is accompanied by 
increased degradation of mature NGF, and that this is likely to 
be an initiating factor in the degeneration of the cholinergic 
neurons [77, 78]. This theory is supported by the observation 
of lower levels of plasmin activity in Alzheimer cortex [78]. 
Following stimulation of cortical tissue, the majority of NGF 
released would be in the proNGF form, and thus conversion 
of proNGF to its mature form would occur mainly in   
the extracellular space. Studies showed that proNGF,   
plasminogen and tPA are released together following   
neuronal stimulation, by addition of neurotransmitters   
or high molarity potassium [77, 78]. Plasminogen is   
then converted to plasmin by tPA, which in turn converts 
proNGF to mature NGF. The reduction in plasmin activity 
results in less cleavage of proNGF to form NGF, and   
explains the increase in proNGF in Alzheimer’s brain tissue. 
Furthermore, one recent study finds reduced tPA activity   
in Alzheimer’s disease cortex but with no change in   
tPA (tissue plasminogen activator) or plasminogen   
protein levels. Neuroserpin levels however, were found to   
be significantly elevated, whilst endogenous plasminogen 
activator inhibitor-1 and protease nexin-1 levels were   
unchanged. It seems likely then that neuroserpin inhibition of 
tPA activity leads to reduced plasmin activity [79]. 
    Any mature NGF which is produced then interacts 
with its receptors or is degraded by proteases such as matrix 
metalloproteinase 9 (MMP-9), which under normal condi-
tions is also activated from its pro form by plasmin [78]. 
Cuello suggests that the apparent disparity can be explained 
by a corresponding increase in other MMP9 activating   
factors such as nitric oxide (NO) [78]. NO is produced from 
inducible NOS (iNOS) which is associated with inflammatory 
responses, or increased oxidative stress due to ischaemia   
or hyperglycemia, and is increased in Alzheimer’s disease. 
An overall increase in MMP9 activity would result in a   
decrease in endogenous NGF, which would contribute   
to cholinergic atrophy. A summary of this is in Fig. (3). In 
addition, experiments show that prolonged inhibition of 
plasmin activity results in reduction in density of cortical 
cholinergic presynaptic terminals, as measured by vesicular 
acetyl choline transporter (VAChT) immunoreactivity [78].  
ProNGF Signalling  
  As mentioned above, signalling through p75NTR is 
complex due to its many interacting receptors and it has   
the ability to elicit ligand-dependent and independent,   
trophic or apoptotic effects [80]. Although p75NTR-
mediated apoptosis has been reported following proNGF 
binding [81], it has recently been shown that proNGF can 
also have trophic effects by binding TrkA [82-84]. This is 
with a ten to twentyfold less potency than mature NGF, 
commensurate with its lower affinity for TrkA [82]. 
  The receptor sortilin has been shown to be a necessary 
p75NTR co-receptor for proNGF-mediated apoptosis [47]. 
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which are important in endocytosis and receptor recycling 
and trafficking. Sortilin is produced in dendrites, axons and 
nerve terminals in perinuclear vesicles and the TGN. It is 
predominantly intracellular, but a small percentage exists at 
the plasma membrane. The redistribution of sortilin from the 
lysosome to the cell surface is regulated by the p75NTR co-
receptor NRH2, and this has a vital role in making sortilin 
available for association with p75NTR [85]. Sortilin   
mediates internalization of proNGF to recycling endosomes, 
where release of the intracellular domain of p75NTR occurs; 
this results in nuclear translocation of NRIF (neurotrophin 
receptor interacting factor), and subsequent cell death [86]. 
Pro-apoptotic effects through p75NTR can also be via JNK 
activation; for instance through the p75NTR cytosolic region 
binding NRAGE (neurotrophin receptor-interacting MAGE 
homolog) [87]. 
  However, no difference in protein levels of sortilin   
have been reported in hippocampus or basal forebrain from 
Alzheimer patients compared with normal [82, 88]. Never-
theless sortilin is implicated in age-related neurodegenera-
tion [89] and proNGF has been shown to elicit cell death in 
basal forebrain slices from aged but not young mice [90, 91]. 
This has been attributed to increased sortilin levels with age.  
  Thus, although there are number of hypotheses   
surrounding the changes seen in NGF and TrkA, the exact 
mechanisms, and the order in which they occur, have yet to 
be determined.  
BDNF AND SYNAPTIC PLASTICITY  
BDNF and Long Term Potentiation 
  BDNF is highly expressed and widely distributed 
throughout the central nervous system especially in the   
hippocampus and cerebral cortex [92-93] and is important  
in the survival and function of hippocampal, cortical,   
cholinergic and dopaminergic neurons [94-97]. It not   
surprising therefore that it has been associated with a number 
of disorders of the brain, including Alzheimer’s disease, 
Huntington's disease [98], depression [99] schizophrenia 
[100] and Rett syndrome [101]; with changes in BDNF   
levels being associated with each of these conditions.  
  In addition to maintaining these various neuronal groups, 
BDNF has another important role: as a key molecule in   
synaptic plasticity. Long-term potentiation (LTP) is a   
component of synaptic plasticity, which involves an   
increase in synaptic strength usually induced by high   
frequency stimulation [102]. In the hippocampus and limbic 
structures, LTP provides the cellular mechanism for memory 
acquisition and consolidation.  
  LTP is classically subdivided into early and late forms 
(E-LTP and L-LTP); BDNF is of profound importance to 
both forms of LTP [104]. E-LTP requires modification of 
proteins but not de novo synthesis; BDNF assists induction 
of E-LTP by acting through TrkB to increase the synaptic 
response to weak tetanus stimulation [105]. L-LTP, is   
produced with strong high frequency stimulation, is protein  
synthesis dependent and is associated with structural changes 
at synapses [106]. After induction of L-LTP, Ca
2+ influx 
occurs through NMDA (N-methyl-d-aspartate) receptors   
or voltage-gated Ca
2+ channels leading to secretion of   
BDNF [107]. BDNF then binds to TrkB localized at pre- or 
postsynaptic glutamatergic synapses [108]; at postsynaptic 
sites, TrkB associates with NMDA receptors and PSD95 
(post synaptic density 95) [109].  
  Removal or reduction of BDNF, using BDNF antisense 
[110, 111], anti-BDNF antibodies [112] or in BDNF   
heterozygous knockout mice [113-115] produces a marked 
deficit in L-LTP. Furthermore, BDNF heterozygous   
knockouts have a reduction in hippocampal axon collaterals 
and varicosities [116] and profound spatial memory and 
learning deficits. L-LTP can be rescued in these mice by 
viral transfer of BDNF [117], even when all new protein 
synthesis is blocked [114], suggesting that it may be the only 
protein required to maintain L-LTP. Likewise TrkB is   
required for L-LTP; anti-TrkB treatment in hippocampal 
slices inhibits L-LTP [118], and loss of the full length   
catalytic form of TrkB, as in the conditional TrkB knockout 
mice, results in severe impairment of learning [119, 120]. 
ProBDNF and Long Term Depression 
  Induction of LTP results in the increased formation of 
synapses at dendritic spines or axon collaterals [121].   
Conversely, long term depression (LTD) entails a reduction 
in synaptic strength, and is usually induced experimentally 
by low-frequency stimulation [122]. Whereas BDNF and TrkB, 
but not p75NTR, are important in LTP [114], proBDNF, via 
 
 
 
 
Fig. (3). ProNGF and NGF interactions with receptors. In normal brain (white arrows), proNGF is processed to NGF extracellularly by 
plasmin, and intracellularly by furins. NGF acts at TrkA, facilitated by p75NTR. This leads to acetylcholine release and activation of M1 
muscarinic receptors which leads to increased alpha-secretase activity, which is counter to A production. In Alzheimer brain (arrows in 
black) proNGF is not processed properly to NGF. The increased level of proNGF will lead to increased binding at p75NTR and probably 
sortilin, leading to a greater likelihood of cell death. Due to an increase in MMP9 activity NGF is degraded more quickly. Thus less acetyl-
choline will be released, less communication with other neurons, less activation of M1 receptors and an increase in beta-secretase activity. 
The latter will lead to an increase in A formation. Length and thickness of arrows denotes strength of activity. The Neurotrophins and their Role in Alzheimer’s Disease  Current Neuropharmacology, 2011, Vol. 9, No. 4    565 
binding at p75NTR, is important in LTD [114, 123, 124]. 
There are contradictory studies as to the extent of processing 
of proBDNF to BDNF, whether this occurs intracellularly or 
extracellularly, by which protease, and whether proBDNF 
can remain unprocessed long enough to have a role in LTD 
[125-127]. This may partly depend upon where BDNF 
mRNA is situated within the neuron. For instance, transcripts 
of BDNF are polyadenylated at two alternative sites   
producing a short and long version of 3 UTR, which   
are involved in different cellular functions. In hippocampal 
neurons, the short 3 UTR mRNAs are restricted to   
soma, whereas the long 3 UTR mRNAs are also localized in 
dendrites, where they are important for dendritic pruning.  
BDNF Processing and Regulated Secretion  
  The processing pathway of BDNF is therefore extremely 
important in determining the outcome of synaptic remodel-
ling. ProBDNF is processed to BDNF by furin within the 
endoplasmic reticulum or proconvertases in secretory vesi-
cles, or extracellularly by plasmin; thus mature BDNF is then 
able to bind TrkB facilitating LTP (127; Fig. 4). Whereas 
proNGF, proNT-3 and proNT-4 are all largely processed via 
a nonregulated secretory pathway, proBDNF is able to be 
sorted to a regulated secretory pathway [128-129], through 
interacting with the sorting receptor carboxypeptidase E 
[130]. BDNF has a motif (Ile16, Glu18, Ile105, Asp106) 
within the mature protein [130], mutation of which resulted 
in mis-sorting of pro-BDNF to the constitutive pathway. 
Thus mutated BDNF was located mostly in the perinuclear 
region, whereas wild-type BDNF occurred in a punctuate 
manner along cell processes. Conversely, when NGF   
was mutated to contain this sorting motif, it became partially 
redirected to the regulated pathway [130]. Furthermore,   
carboxypeptidase E knockout mice showed no activity-
dependent secretion of BDNF in cortical neurons [130],   
although mature BDNF was released via the constitutive 
pathway. 
  In addition to the motif within the mature region which 
interacts with carboxypeptidase E, BDNF also has a motif 
within the prodomain which affects secretion [131]. Sortilin 
was shown to interact with proBDNF via this motif and to 
colocalize with proBDNF in secretory granules in neurons. 
Down regulation of sortilin by small interfering RNA 
(siRNA) in primary neurons led to proBDNF missorting to 
the constitutive secretory pathway. Thus the presence of a 
common BDNF polymorphism in the pro-region of proBDNF 
(Val66Met; 19-45% in varying populations [132]), in   
the region of the sortilin binding site, resulted in impaired 
regulated secretion of BDNF after potassium depolarization 
[133]. Cultured hippocampal neurons transfected with the 
Met66 proBDNF did not show the Val66-associated proBDNF 
colocalization with synaptic markers in dendritic processes, 
but showed perinuclear clustering, indicating that proBDNF 
sorting from the Golgi complex was affected [133]. Subjects 
carrying this polymorphism have been shown to be less   
successful in tests of episodic short-term memory, and   
functional MRI (magnetic resonance imaging) shows   
differences in glucose utilization [133, 134]. They also have 
a smaller hippocampus and prefrontal cortex [135].  
   The sorting of proBDNF for regulated secretion therefore 
probably involves primary interaction between the   
pro-domain and sortilin, which promotes an appropriate   
protein conformation of proBDNF. The sorting motif in   
the mature domain of BDNF subsequently interacts with 
carboxypeptidase E, and sorts BDNF into the regulated   
secretory pathway. The prodomain may therefore be   
necessary, but not sufficient to sort BDNF into the regulated 
pathway. ProNGF, despite having no sorting motif in the 
mature domain, which prevents it from entering the regulated 
secretory pathway, has the required binding motif to enable 
binding to sortilin. This promotes correct folding during 
maturation, but also facilitates its internalisation via sortilin 
and p75NTR to elicit intracellular signalling.  
BDNF, ALZHEIMER’S DISEASE AND DEPRESSION 
BDNF and Depression 
  It has been noted that a large percentage of Alzheimer 
patients suffer from depression, and moreover that severe 
depression can sometimes produce symptoms similar to early 
Alzheimer’s disease. Serotonergic pathways are markedly 
affected in Alzheimer’s disease and this may account to 
some extent for the associated depression. Reductions in 
serum BDNF levels have been reported in patients with   
depressive disorders [136], whereas increased BDNF levels 
are seen following antidepressant treatment [137]. It is known 
that the expression of BDNF is trophic for serotonergic   
neurons [138], and that serotonin stimulates BDNF   
production. This is in accordance with the finding that SSRIs 
(selective serotonin uptake inhibitors), commonly used as 
antidepressants, increase brain BDNF levels. BDNF mRNA 
levels in the hippocampus have also been shown to be   
significantly increased with physical exercise [139] and   
electroconvulsive therapy [140], which is sometimes used as 
a treatment for depression. The influence of the Val66Met 
polymorphism on depression is difficult to assess in the   
light of the disparity of results from a number of studies. 
However, in general, there appears to be some relationship 
 
 
 
 
Fig. (4). ProBDNF and BDNF interactions with receptors. In normal brain (white arrows), proBDNF is processed to BDNF extracellularly by 
plasmin, or intracellularly by furins or proconvertases. BDNF acts at TrkB facilitating LTP. This leads to synapse strengthening. In Alzheimer 
brain (arrows in black) proBDNF is downregulated (perhaps directly due to A), thus BDNF levels are reduced. This will lead to a reduction in 
LTP and synapse formation. Length and thickness of arrows denotes strength of activity. Question marks denote unknowns. 566    Current Neuropharmacology, 2011, Vol. 9, No. 4  Allen et al. 
between the presence of this polymorphism and likelihood of 
depression or recovery with antidepressants [141]. 
BDNF and Alzheimer’s Disease 
  It has been suggested that the early memory dysfunction 
seen in Alzheimer’s disease may be related to the levels of 
BDNF in the hippocampus. A summary of this is in Fig. (4). 
Evidence to support this includes substantially reduced 
BDNF mRNA levels in Alzheimer’s disease hippocampus 
[142] and parietal cortex [143] and decreased protein   
levels of BDNF in entorhinal cortex, hippocampus, temporal, 
frontal and parietal cortex [144-147]. Unlike mature NGF, 
mature BDNF protein can be visualised by western blotting, 
together with its pro-form. Both forms have now been shown 
to be reduced in Alzheimer’s disease, with a reduction   
in mature BDNF of 23% reported in frontal cortex [146]. 
Furthermore a progressive decrease from normal was seen in 
proBDNF in MCI (21%), compared with Alzheimer (30%) 
parietal cortex [148-150].  
  The changes in BDNF levels however, seem to be due to 
specific downregulation of certain BDNF transcripts. There 
are at least seven BDNF transcripts expressed in human 
brain, and a number of splice variants of these exist [150]. 
Only three of these transcripts have been shown to be down-
regulated in Alzheimer’s brain (I, II, and IV (previously 
named III)). In a study using the human neuroblastoma cell 
line (SH-SY5Y) addition of A42 resulted in down-
regulation of BDNF, specifically through BDNF transcript 
IV, the most abundantly expressed BDNF transcript in   
human cortex [151]. This downregulation may be due to the 
effect of A on CREB phosphorylation. Phosphorylation of 
CREB (transcription factor: cAMP response element-
binding) enables binding to CREB-binding protein (CBP) 
resulting in stimulation of CRE-dependent gene expression. 
Increased A levels cause downregulation of CREB   
phosphorylation with a resultant reduction in CRE-dependent 
gene expression, including BDNF transcription [152].  
  The consensus of a number of studies on the possible 
effect of the Val66Met polymorphism in Alzheimer’s disease 
is that the presence of the Met66 allele is a risk factor, and is 
associated with increased progression to Alzheimer’s disease 
[153, 154]. In addition, other BDNF polymorphisms may 
also be implicated [155].  
  Changes in neurons expressing the BDNF receptor TrkB, 
have also been found in Alzheimer’s disease. Thus, in post-
mortem tissue a 47% reduction in TrkB positive neurons has 
been reported [156], which may be due to a loss of neurons 
or a downregulation of TrkB expression. In addition a   
selective reduction in the TrkB protein catalytic form   
(145 kDa), but not the non catalytic form (95kDa), was 
found in both frontal and temporal cortex in Alzheimer’s 
disease [157]. The non-catalytic form is present on a large 
number of different cell types in the brain, many of which 
may not be affected in Alzheimer’s disease. 
  In summary, there is a marked reduction in BDNF levels 
in both the cortex and ChBF in Alzheimer’s disease, and this 
may have a bearing on support for cholinergic neurons   
as well as a deficit in LTP with wide significance for   
synaptic plasticity in a number of different neurons. With the 
likelihood that the Val66Met polymorphism is a risk factor 
for progression of the disease, we are perhaps moving one 
step closer to personalised therapeutics and to pre-selection 
for drug trials. 
THERAPEUTIC SOLUTIONS ASSOCIATED WITH 
NGF AND BDNF 
In Vitro and In Vivo Animal Studies Associated with NGF 
  NGF has been shown in a large number of studies to   
increase survival and function (often measured by choline 
acetyltransferase activity) of ChBF neurons both in vitro 
[158-161]  and in vivo subsequent to cholinergic lesion.   
Lesioning of the fimbria-fornix in rats is a method routinely 
used to produce deficits in the ChBF. This procedure   
prevents cholinergic terminals in the hippocampus from   
being able to retrogradely transport NGF back to the   
cell bodies in the septal nucleus. This results in atrophy and 
some loss of cholinergic neurons. Infusing NGF into the 
cerebral ventricles, adjacent to the ChBF nuclei, prevents 
this degeneration [162-164] and reverses behavioural deficits 
such as impairment in water maze performance [163-165]. 
Interestingly, some aged animals have also been shown to 
have reduced cholinergic function, and cerebroventricular 
infusion of NGF in this subpopulation of aged rats   
normalises their behaviour [163, 166-168]. 
  Heterozygous NGF knockout mice have reduced levels 
of NGF in the hippocampus, display memory impairment, 
show shrinkage and loss of cholinergic septal cells and   
have decreased cholinergic innervation of the hippocampus. 
Long term infusions of NGF (for five weeks) into the lateral 
ventricles was shown to abolish the memory deficits   
and correct the size (although not number) of cholinergic 
neurons, and also to increase the density of cholinergic   
innervation of the hippocampus [169]. 
An Anti-NGF Model of Alzheimer’s Disease 
  One of the problems with the classic animal models of 
Alzheimer’s disease (e.g. APP mutations) is that they do not 
reflect all of the changes see in Alzheimer’s patients, such  
as loss of cholinergic function or the production of tau   
pathology. In 2001 a transgenic mouse was produced as a 
model of cholinergic deficit. Since NGF knockout mice have 
deficits related to development, a mouse was engineered 
which produced antibodies to NGF which accumulated with 
increasing age. These mice (named AD11) showed a reduction 
in cholinergic cells staining for choline acetyltransferase in 
the basal forebrain and exhibited difficulty in executing 
memory tasks. However, unexpectedly they also showed 
cortical cell loss, and the presence of amyloid plaques and 
hyperphosphorylated tau in the cortex and hippocampus 
[170], suggesting that loss of NGF in adulthood may be   
sufficient to produce Alzheimer-like neuropathology. 
  Intranasal administration of NGF restored cholinergic 
function and reduced the number of amyloid plaques   
and hyperphosphorylated tau deposits [171]. Intraperitoneal 
injection of galantamine also restored the number of choline 
acetyltransferase-immunopositive neurons to normal and 
reduced numbers of amyloid plaques, although this drug was 
unable to reduce deposition of hyperphosphorylated tau 
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Phase I Trial: Infusion of Mouse NGF 
  In the 1990s a small Phase I trial was carried out in   
Sweden in which purified mouse NGF was infused intra- 
cerebroventricularly [172, 173]. In two patients 6.6 mg NGF 
was infused over three months. The third patient was infused 
with three doses of NGF (<0.25 mg) given separately for   
a total of 22 weeks, for a period of more than a year. The 
patients were tested cognitively, with magnetic resonance 
imaging (MRI), positron emission tomography (PET) and 
electroencephalography (EEG). (
11C)-Nicotine binding was 
used as a measure of cholinergic synapses. The first two   
patients showed slight improvements in cognitive testing; 
one of these showed a marked increase in frontal and   
temporal cortical blood flow that continued for several 
months after the NGF treatment had ceased; they also had an 
increase in (
11C)-nicotine binding in the same regions and the 
hippocampus. One of these also showed improvement   
in glucose metabolism. The third patient showed less   
improvement although increased (
11C)-nicotine binding was 
observed in the hippocampus seven months after the end of 
the second period of NGF treatment.  
  However, after 11 days of treatment, the patients   
complained of lumbar pain, which ceased within two days  
of stopping the treatment. Subsequent studies in rats and 
primates showed induction of Schwann cell hyperplasia 
[174]; recombinant human NGF was administered intra- 
cerebroventricularly to rats for 12 weeks, and tissue sections 
were then taken from the region around the surface of the 
medulla and the spinal cord. These showed the presence   
of adherent non-malignant hyperplastic tissue formed from 
proliferating Schwann cells, which stained for p75NTR   
but not TrkA [174]. After stopping the NGF infusion, the 
hyperplasia gradually reduced in size and disappeared after  
a number of weeks. A second study in which recombinant 
human NGF was infused into both rat and primate   
cerebral ventricles showed that hyperplasia was produced in 
a dose-dependent fashion [174].  
  Clearly, this hyperplasia had arisen because of the high 
levels of NGF infused into the ventricles. Other means of 
providing NGF to the brain were then developed. 
Phase I Trial: Implantation of NGF-Producing Fibroblasts 
  In 2001 a Phase I trial of eight early stage Alzheimer’s 
patients assessed the effect of implantation of fibroblasts, 
modified to produce NGF, into the basal forebrain [175]. 
Mark Tuszynski and colleagues at the University of California 
took fibroblasts from each patient, cultured and transfected 
them with a retroviral vector directing the cells to secrete 
human NGF before implantation. Unfortunately, two of the 
patients were severely affected by the intrusive surgical   
procedure, one of whom died; in the six remaining patients 
no undesirable effects were seen for up to 22 months post-
treatment [175]. MMSE scores, which were on average   
declining at a rate of six points per year, slowed to three 
points per year, equivalent to a slowing of the disease by 36–
51%. PET analysis of four subjects (those given a higher cell 
count at implantation) when tested between six and eight 
months after implantation, showed a striking increase of 
fluorodeoxyglucose uptake, to areas receiving cholinergic input 
from the ChBF. In 2008 following examination by autopsy of 
four people from the trial, Tuszynski noted that each subject 
exhibited a clear increase in cholinergic cell growth in   
response to NGF, and concluded that “additional clinical 
trials of NGF for Alzheimer’s disease are warranted” [176].  
Further Trials of NGF 
  Whilst problems had been encountered with administra-
tion of NGF, other methods of delivery have been devised. 
Ceregene Inc. (San Diego) successfully carried out a Phase I 
study to assess adeno-associated virus (AAV) mediated   
delivery of NGF (CERE-110; AAV2-NGF). CERE-110 is   
an AAV serotype 2-based vector producing human NGF 
administered by stereotactic injection to the nbM [177]. A 
USA based multicentre Phase II clinical trial has now begun 
recruiting patients for a randomized, controlled study in up 
to fifty subjects with mild to moderate Alzheimer's disease, 
with half of the patients due to undergo a placebo surgery 
with no medication injected.  
In Vitro and In Vivo Animal Studies Associated with 
BDNF 
  BDNF administration into the entorhinal cortex in animal 
models of Alzheimer’s disease recently produced promising 
therapeutic results [178]. The entorhinal cortex is one of the 
first areas affected in Alzheimer’s disease; TrkB receptors 
are expressed there and it is a major provider of BDNF 
through its input to the hippocampus. In transgenic mice 
with APP mutations, lentiviral vectors expressing BDNF 
were injected into the entorhinal cortex, an area with   
amyloid plaques and cell loss. This did not affect either the 
neuronal number or amyloid plaque density; yet recovery of 
synapses and improved cell signaling was seen, together with 
amelioration of spatial memory deficits. Similarly in aged 
rats (24 months old), bilateral, 28 day infusions of BDNF 
improved spatial learning and memory in water maze   
performance, and restored cell signaling. Furthermore,   
improvements were also seen in aged primates, where BDNF 
gene delivery to the entorhinal cortex reversed neuronal   
atrophy and ameliorated age-related cognitive impairment. 
The authors point out that this approach could be scaled up 
to deliver BDNF to the human entorhinal cortex, and that the 
“potency of BDNF seen in the preclinical models provides a 
rationale for exploring clinical translation” [178]. 
  In addition, since SSRI antidepressants are known to   
elevate BDNF levels, research and clinical trials are being 
carried out to investigate the effect of these in Alzheimer’s 
disease; one such antidepressant, Citalopram, is currently 
undergoing Phase II clinical trials.  
Small Molecule Therapeutics 
  Future directions in NGF and BDNF-based therapies may 
target the neurotrophin receptors. Modulation of p75NTR by 
a small molecule ligand has already been suggested as a way 
of preventing p75NTR-mediated cell death. LM11A-24 and -
31 are small molecules which block the effect of this receptor 
with low nanomolar potency, and are reported to prevent   
A induced cell death and inhibit tau phosphorylation [179]. 
Derivatives of these compounds have been described as   
candidates for clinical development. In addition small   
m o l e c u l e  m i m e t i c s  o f  N G F  o r  B D N F  h a v e  a l s o  b e e n    
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screening with a BDNF loop–domain pharmacophore,   
Longo and colleagues have identified small molecules with  
nanomolar neurotrophic activity at TrkB, which prevented 
neuronal degeneration and improved motor learning after 
traumatic brain injury in rats. These are being taken forward 
as lead compounds for future treatments [181]. 
SUMMARY 
  The neurotrophins NGF and BDNF are associated with 
the early changes seen in MCI leading on to Alzheimer’s 
disease. Notably an increase in proNGF is seen in the cerebral 
cortex, together with a loss of Trk receptors in the ChBF 
neurons, with no change in p75NTR or sortilin receptors.   
In conjunction with this are reductions in both BDNF   
and proBDNF in the cortex and hippocampus. There are 
various theories as to how this occurs and how it affects the 
progression of the disease. Firstly, it is likely that A is the 
initiating factor; it is able to bind to a number of receptors, 
has significant deleterious effects in the mitochondria, and is 
able to modify gene expression. However, the specific effects 
on the neurotrophins and their receptors are important at the 
site most vulnerable early in the disease, the hippocampus, 
and may be crucial in the development of the disease.  
  A model of Down’s syndrome, itself a “model” of   
Alzheimer’s disease, has virtually no retrograde transport of 
NGF to the ChBF cell bodies, and it is possible that likewise 
there is a defect in retrograde transport of NGF in   
Alzheimer’s disease. This would account for the low level of 
mature NGF in the cholinergic cells. Another hypothesis 
gaining credence is that the processing of proNGF to NGF  
is impaired, due to a decrease in the activity of plasmin,   
a protease which cleaves proNGF. It is interesting also   
that plasmin probably helps to regulate A levels in the 
brain, along with other enzymes such as neprilysin and   
insulin-degrading enzyme. An increase in MMP9, perhaps 
due to the increased NO levels seen in Alzheimer’s disease, 
may then give rise to an increase in the degradation of NGF.  
  In parallel with this, or perhaps because of this, there is  
a loss in Trk receptors on the ChBF neurons, even in MCI. 
Currently one favoured theory is that p75NTR signalling in 
response to proNGF, whether pro-survival or pro-apoptotic 
may depend upon the ratio of TrkA /p75NTR in the ChBF 
and NGF/proNGF levels produced in the target tissues.   
Thus the decrease in TrkA, with no change in p75NTR or 
sortilin levels, will alter the outcome of proNGF effects on 
the neuron, promoting pro-apoptotic rather than trophic 
events. 
  Current NGF-related therapeutic intervention continues 
with clinical trials using viral transfer of NGF-producing 
capability into the brains of Alzheimer’s patients, and   
alongside is the possibility of small molecule intervention at 
TrkA or p75NTR. 
  The change seen in BDNF levels does not seem to reflect 
the same pattern as that of NGF. There is a reduction in 
proBDNF as well as BDNF and this may be due to the   
difference in processing of proBDNF compared with 
proNGF. However the downregulation of BDNF may be at a 
gene level and may be connected with interference by A 
with CREB. The loss of BDNF, considering its importance 
in synaptic plasticity, may explain the reduction in synapses 
seen in early stage Alzheimer’s disease.  
  As with NGF, BDNF therapy in animals by infusion   
or viral transfer seems to successfully ameliorate cognitive 
impairment. It is expected that this will eventually be   
translated into a clinical setting. The possibility of using 
small molecule TrkB agonists is also being investigated. 
  It may be that NGF or BDNF-associated treatment   
will be important in the future as early stage therapeutics for 
Alzheimer’s, whether or not the initial cause is neurotrophin 
related. However, in order to provide the most effective and 
sustainable treatment, there must also be an understanding of 
what is happening at a molecular level before even the first 
symptoms appear, and the role that neurotrophins and their 
receptors play in this. 
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